Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.806 SEK
−249.11 M SEK
35.22 M SEK
127.15 M
About ONCOPEPTIDES AB
Sector
CEO
Sofia Heigis
Headquarters
Stockholm
Website
Founded
2000
ISIN
SE0009414576
FIGI
BBG00FYBPDP1
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ONCO is 1.556 SEK — it has increased by 2.96% in the past 24 hours. Watch ONCOPEPTIDES AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ONCOPEPTIDES AB stocks are traded under the ticker ONCO.
ONCO stock has risen by 1.87% compared to the previous week, the month change is a 1.87% rise, over the last year ONCOPEPTIDES AB has showed a −71.31% decrease.
We've gathered analysts' opinions on ONCOPEPTIDES AB future price: according to them, ONCO price has a max estimate of 14.00 SEK and a min estimate of 1.50 SEK. Watch ONCO chart and read a more detailed ONCOPEPTIDES AB stock forecast: see what analysts think of ONCOPEPTIDES AB and suggest that you do with its stocks.
ONCO reached its all-time high on Mar 1, 2021 with the price of 153.218 SEK, and its all-time low was 1.426 SEK and was reached on Nov 19, 2024. View more price dynamics on ONCO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ONCO stock is 4.47% volatile and has beta coefficient of 0.18. Track ONCOPEPTIDES AB stock price on the chart and check out the list of the most volatile stocks — is ONCOPEPTIDES AB there?
Today ONCOPEPTIDES AB has the market capitalization of 322.81 M, it has decreased by −2.50% over the last week.
Yes, you can track ONCOPEPTIDES AB financials in yearly and quarterly reports right on TradingView.
ONCOPEPTIDES AB is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
ONCOPEPTIDES AB revenue for the last quarter amounts to 8.50 M SEK, despite the estimated figure of 14.00 M SEK. In the next quarter, revenue is expected to reach 12.00 M SEK.
ONCO net income for the last quarter is −60.23 M SEK, while the quarter before that showed −73.24 M SEK of net income which accounts for 17.76% change. Track more ONCOPEPTIDES AB financial stats to get the full picture.
No, ONCO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 57.00 employees. See our rating of the largest employees — is ONCOPEPTIDES AB on this list?
Like other stocks, ONCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOPEPTIDES AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOPEPTIDES AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOPEPTIDES AB stock shows the sell signal. See more of ONCOPEPTIDES AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.